# A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

> **NCT01293630** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 18 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Ombrabulin (AVE8062)
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01293630
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01293630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01293630, "A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01293630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*